Share Article
Healthcare professionals and people living with HIV in the United States can learn more about Viread by logging on to www.Viread.com. Designed as a comprehensive resource, the site provides user-friendly clinical and educational information, as well as links to other HIV/AIDS Internet sites. Viread.com was developed by Ignite Communications (www.ignitenow.com), an interactive healthcare agency based in San Juan Capistrano.
About Viread
In the United States, Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts in a controlled study of Viread of 24 weeks duration and in a controlled, dose ranging study of Viread of 48 weeks duration. Both studies were conducted in treatment-experienced adults with evidence of HIV-1 viral replication despite ongoing antiretroviral therapy. Studies in antiretroviral-naive patients are ongoing; consequently, the risk-benefit ratio for this population has yet to be determined.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.
Note to Editors: Viread is a trademark of Gilead Sciences, Inc.
For more information on Gilead Sciences, please visit the company's Web site at www.gilead.com or call the Gilead Corporate Communications Department at 1-800/GILEAD-5 (1-800/445-3235).
CONTACT: Gilead Sciences, Foster City
Susan Hubbard, 650/522-5715 (Investors)
Erin Edgley, 650/522-5635 (Media)
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.
Other News
Some of the content on this page is not intended for users outside the U.S.